Match Document Document Title
7163810 Method for producing target substance  
In a method for producing a target substance by using a microorganism comprising culturing a microorganism having an ability to produce the target substance in a medium to produce and accumulate...
7160988 Altering protein functional properties through terminal fusions  
We disclose isolated terminal fusion polypeptides comprising a soybean glycinin or proglycinin polypeptide operably linked to the peptide of SEQ ID NO:12.
7160985 Pro180 polypeptide  
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid...
7157091 MAGE-A1 peptides presented by HLA class II molecules  
The invention provides isolated HLA DRB1*15-binding peptides consisting of the amino acid sequence set forth as SEQ ID NO:7 with 0–10 amino acids added to either or both ends of the amino acid...
7157089 Immune responses using compositions containing stress proteins  
The present invention relates to a vaccine for inducing an immune response to an antigen in a vertebrate (e.g., mammal) comprising an antigen and all or a portion of a stress protein or all or a...
7153509 Immunogenic peptides comprising a T-helper epitope and a B-cell neutralizing antibody epitope  
The present invention relates, generally, to a polyvalent immunogen and, more particularly, to a method of inducing neutralizing antibodies against HIV and to a polyvalent immunogen suitable for...
7150875 Recombinant Plasmodium vivax merozoite protein-1 p42 vaccine  
In this application is the expression and purification of a recombinant Plasmodium vivax (SalI) PvMSP-1 p42. The method of the present invention produces a highly purified protein which retains...
7151163 Antiviral agents for the treatment, control and prevention of infections by coronaviruses  
The invention provides compositions and methods that are useful for preventing and treating a coronavirus infection in a subject. More specifically, the invention provides peptides and conjugates...
7148061 Identification of a novel domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function  
The present invention provides a polypeptide comprising the isolated amino acid sequence of a pre-ligand assembly domain (PLAD) of a TNF-like receptor. Also provided by this invention is a...
7144581 Compositions and methods for WT1 specific immunotherapy  
Compositions and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The compositions comprise one or more of a WT1 polynucleotide, a WT1 polypeptide, an...
7144712 Human hepatitis B virus core proteins as vaccine platforms and methods of use thereof  
The present invention relates to hepatitis virus core proteins and nucleic acids. In particular, the present invention provides compositions and methods comprising recombinant hepatitis virus core...
7138274 Advanced oral poliovirus vaccine (Adv-OPV) deprived of the possibility of vaccine associated paralytic poliomyelities (VAPP)  
The present invention relates to a novel recombinant Sabin type 1 poliovirus vector for the immunogenicity of neutralizing antibody against polioviral infection, which comprises: (a) a genomic...
7135556 NPC1L1 (NPC3) and methods of use thereof  
We claim an isolated polypeptide having ability of binding with cholesterol. Said polypeptide is useful for investigating regulation of intestinal cholesterol absorption and cholesterol levels....
7135185 Conserved motif of hepatitis C virus E2/NS1 region  
Immunogenic compositions comprising an immunogenic polypeptide and a pharmaceutically acceptable vehicle are described. The immunogenic polypeptide comprises the amino acid sequence...
7135176 VMP-like sequences of pathogenic Borrelia  
The present invention relates to DNA sequences encoding Vmp-like polypeptides of pathogenic Borrelia , the use of the DNA sequences in recombinant vectors to express polypeptides, the encoded...
7135188 Methods and compositions for immunotherapy of cancer  
Methods and vaccines for suppressing formation of or inhibiting growth of tumors in a host are provided, via administration of a vaccine containing either a fusion protein of the tumor associated...
7132512 Medicament for the treatment of chlamydial infection  
The present invention concerns treatment, prevention and diagnosis of infection due to Chlamydia pneumoniae and, in particular, to the prevention and treatment of atherosclerosis, including...
7129069 Hybrid enzymes  
The present invention relates to a hybrid enzyme comprising at least one carbohydrate-binding module amino acid sequence and at least the catalytic module of a glucoamylase amino acid sequence. The...
7129330 Multivalent antibody constructs  
The present invention relates to multivalent F v antibody construct having at least four variable domains which are linked with each over via the peptide linkers 1, 2 and 3. The invention also...
7128905 Method of treating graft versus host disease by administration of a Fas antagonist  
The present invention is drawn to methods of preventing and treating diseases wherein the involvement of apoptosis has been indicated.
7125699 Identification of a human N-terminal acetyltransferase gene  
HUTUDO1 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods utilizing HUTUDO1 polypeptides and...
7122631 Secreted and transmembrane polypeptides and nucleic acids encoding the same  
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid...
7122516 Stabilized bioactive peptides and methods of identification, synthesis and use  
An intracellular selection system allows concurrent screening for peptide bioactivity and stability. Randomized recombinant peptides are screened for bioactivity in a tightly regulated expression...
7122190 Fusion proteins comprising DP-178 and other viral fusion inhibitor peptides useful for treating aids  
The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID:1) peptide corresponding to amino acids 638 to 673 of...
7118752 Compositions and methods for inhibiting the proliferation and invasiveness of malignant cells comprising E-domain peptides of IGF-I  
A method is described for using an a-type or b-type E domain of the human or trout IGF peptide for the inhibition of proliferation and invasiveness of a broad spectrum of malignant cells and for...
7118751 DNA vaccines encoding antigen linked to a domain that binds CD40  
Vaccines that target one or more antigens to a cell surface receptor improve the antigen-specific humoral and cellular immune response. Antigen(s) linked to a domain that binds to a cell surface...
7118750 Modified TNF-alpha molecules, DNA encoding such and vaccines comprising such modified TNF-alpha and DNA  
A modified human TNFα molecule is capable of raising neutralizing antibodies towards unmodified human TNFα following administration of the modified TNFα to a human host, wherein one or more...
7115260 Interleukin-1β converting enzyme like apoptotic protease-6  
Human ICE LAP-6 polypeptides and DNA (RNA) encoding such ICE LAP-6 and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing...
7115271 Protein D—an IgD-binding protein of Haemophilus influenzae  
A novel surface exposed protein of Haemophilus influenzae or related Haemophilus species is described. The protein named protein D is an Ig receptor for human IgD and has an apparent molecular...
7112436 Conjugate for modifying interactions between proteins  
The present invention concerns a conjugate comprising two polypeptides with a mutual affinity, the polypeptides being connected with each other via a linker. This invention also concerns the use of...
7112655 JTT-1 protein and methods of inhibiting lymphocyte activation  
A cell surface molecule that is expressed specifically in thymocytes, lymphocytes activated by ConA-stimulation, and peripheral blood lymphocytes. This molecule is involved in signal transmission...
7105166 Soluble CTLA4 mutant molecules and uses thereof  
The present invention provides soluble CTLA4 mutant molecules which bind CD80 and/or CD86 antigen.
7101556 Preparation and usage of plasmodium fusion antigen  
The invention provides a fusion protein comprising the Plasmodium merozoite surface protein-1 (MSP1) and the Plasmodium apical membrane antigen 1 (AMA-1), the encoding DNA sequence, the vector...
7101555 Mycobacterial proteins, microorganisms producing them and their use for vaccines and the detection of tuberculosis  
Mycobacterium tuberculosis protein having a molecular weight of 28 779 Da, and hybrid proteins containing at least portions of its sequence. These proteins may in particular be used in vaccines...
7098303 Conserved motif of hepatitis C virus E2/NS1 region  
Immunogenic polypeptides comprising hepatitis C virus (HCV) immunogens are described. The HCV immunogen comprises the amino acid sequence...
7097841 Ferritin fusion proteins for use in vaccines and other applications  
An isolated ferritin fusion protein is provided in which ferritin is fused with a protein or peptide capable of being fused to ferritin without interfering with the polymeric self-assembly of the...
7097965 Targeting antigens to the MHC class I processing pathway with an anthrax toxin fusion protein  
The present invention provides a vaccine for inducing an immune response in mammal to a specific antigen, where the vaccine comprises a unit dose of a binary toxin protective antigen and the...
7094405 Peptides which elicit a high neutralizing antibody titer, cytotoxic T lymphocyte response and T helper cell response in a broad range of MHC type recipients  
Peptide constructs comprised of multideterminant T helper peptides from the envelope glycoprotein of HIV previously identified to induce proliferative responses in four different haplotypes of mice...
7094409 Antigen arrays for treatment of allergic eosinophilic diseases  
The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or...
7094408 Immunogenicity using a combination of DNA and vaccinia virus vector vaccines  
This invention relates to improved methods of inducing an immune response for the prevention or treatment of HIV-1 infection by using a nucleic acid vaccine in conjunction with a recombinant viral...
7094874 Soluble CTLA4 mutant molecules  
The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4...
7094407 Fusion peptide containing human type-1 collagen derived peptide, preparation thereof, and skin anti-aging cosmetic composition comprising the same  
The present invention relates to a fusion peptide, in which a self cell-penetrating Tat peptide having a self penetrating signal is bound to a human Type-I collagen C-terminal derived peptide, a...
7090847 Mammalian cytokines; related reagents and methods  
Purified genes encoding cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this molecule are provided. Methods of using...
7087235 Fusion protein of streptococcal pyrogenic exotoxins  
The present invention relates to genetically attenuated superantigen toxin vaccines altered such that superantigen attributes are absent, however the superantigen is effectively recognized and an...
7087574 Brain associated inhibitor of tissue-type plasminogen activator  
The present invention relates to a novel BAIT protein which is a member of serpin superfamily which is expressed primarily in brain tissue. In particular, isolated nucleic acid molecules are...
7087225 Methods and compositions for treating metabolic bone diseases relating to human endokine alpha  
The present invention concerns methods for diagnosis and treatment of metabolic bone diseases and disorders using a novel member of the tumor necrosis factor (TNF) family of cytokines. In...
7087410 Systems for expression of heterologous proteins in M. capsulatus  
The present invention relates to an expression system for the expression of proteins and peptides in a methanotrophic bacterium, preferable the M. capsulatus . Further, the invention relates to...
7083796 Fusion proteins of mycobacterium tuberculosis  
The present invention relates to compositions and fusion proteins containing at least two Mycobacterium sp. antigens, and nucleic acids encoding such compositions and fusion proteins. The...
7083950 High affinity fusion proteins and therapeutic and diagnostic methods for use  
High affinity fusion proteins (“trapbodies”), capable of binding and inhibiting the activity of soluble, interacting proteins (“SIPs”) are described. The trapbodies are multimers,...
7083777 Immunomodulating polymers  
A pharmaceutical composition consisting of identical repeating units, each unit having a charge motif composed of a positively charged free amino moiety and a negatively charged moiety, wherein the...